Printer Friendly

UPJOHN ENTERS AGREEMENT WITH LEO PHARMACEUTICAL PRODUCTS

 UPJOHN ENTERS AGREEMENT WITH LEO PHARMACEUTICAL PRODUCTS
 KALAMAZOO, Mich., Sept. 1 /PRNewswire/ -- The Upjohn Company


(NYSE: UPJ) announced today that it has entered into a licensing agreement with Leo Pharmaceutical Products, Ltd., a Danish corporation. Under terms of the agreement, Leo has granted Upjohn an exclusive license for worldwide marketing of a class of pyridyl cyanoguanidine compounds for the treatment of alopecia (hair loss).
 Upjohn will have sole responsibility for the development of these compounds, which are in preclinical testing. Further details of the agreement were not disclosed.
 "This agreement reemphasizes Upjohn's ongoing commitment to hair growth research and our dermatology division," said Jerry R. Mitchell M.D., Ph.D., executive vice president and president, Upjohn Laboratories.
 Leo Pharmaceutical products is a mid-sized, research-based pharmaceutical company with headquarters near Copenhagen, Denmark. It has subsidiaries located in the major European countries and Canada, as well as licensees and agents throughout the world. Recently, Leo has devoted significant research efforts within the field of dermatology.
 The Upjohn Company is a worldwide, research-based provider of human health care products, animal health products, agronomic and vegetable seeds and specialty chemicals. Headquartered in Kalamazoo, the company has been dedicated to improving health and nutrition for more than a century.
 -0- 9/1/92
 /CONTACT: John P. Lambrechts of The Upjohn Company, 616-323-7076/
 (UPJ) CO: The Upjohn Company; Leo Pharmaceutical Products, Ltd. ST: Michigan IN: MTC SU: LIC


ML -- DE007 -- 5299 09/01/92 09:44 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 1, 1992
Words:241
Previous Article:TELEPANEL SYSTEMS ISSUES STATEMENT ON TRADING ACTIVITY IN STOCK
Next Article:CALFED INC. MAKES EXCHANGE OFFER FILING
Topics:


Related Articles
UPJOHN ACQUIRES GERMAN COMPANY
UPJOHN COMPLETES ACQUISITION OF PAKISTAN COMPANY
UPJOHN CONSUMER PRODUCTS DIVISION ENTERS INTO MARKETING AGREEMENT WITH MCNEIL CONSUMER PRODUCTS COMPANY
GENEVA PHARMACEUTICALS AND UPJOHN ANNOUNCE AGREEMENT
GENEVA PHARMACEUTICALS AND UPJOHN EXTEND AGREEMENT
MOTRIN IB SINUS CAPLETS INTRODUCED
FDA ADVISORY COMMITTEE RECOMMENDS LUVOX (FLUVOXAMINE) TABLETS FOR OBSESSIVE COMPULSIVE DISORDER
MGI PHARMA GRANTS CANADIAN RIGHTS FOR SALAGEN(R) TABLETS TO UPJOHN CANADA
INCYTE AND UPJOHN SIGN $20 MILLION DATABASE ACCESS AGREEMENT
Pharmacia & Upjohn Recovers Genotropin Marketing Rights in Japan

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters